T Cell Repertoire Formation and Molecular Mimicry in Rheumatoid Arthritis

Author(s):  
B.J. Prakken ◽  
D.A. Carson ◽  
S. Albani
1998 ◽  
Vol 95 (24) ◽  
pp. 14447-14452 ◽  
Author(s):  
U. G. Wagner ◽  
K. Koetz ◽  
C. M. Weyand ◽  
J. J. Goronzy

2008 ◽  
Vol 10 (6) ◽  
pp. R135 ◽  
Author(s):  
Francesco Ria ◽  
Romina Penitente ◽  
Maria De Santis ◽  
Chiara Nicolò ◽  
Gabriele Di Sante ◽  
...  

Diabetologia ◽  
1996 ◽  
Vol 39 (2) ◽  
pp. 246-247 ◽  
Author(s):  
H. Baum

2021 ◽  
Vol 6 (58) ◽  
pp. eabe0896
Author(s):  
Jia Jia Lim ◽  
Claerwen M. Jones ◽  
Tiing Jen Loh ◽  
Yi Tian Ting ◽  
Pirooz Zareie ◽  
...  

Individuals expressing HLA-DR4 bearing the shared susceptibility epitope (SE) have an increased risk of developing rheumatoid arthritis (RA). Posttranslational modification of self-proteins via citrullination leads to the formation of neoantigens that can be presented by HLA-DR4 SE allomorphs. However, in T cell–mediated autoimmunity, the interplay between the HLA molecule, posttranslationally modified epitope(s), and the responding T cell repertoire remains unclear. In HLA-DR4 transgenic mice, we show that immunization with a Fibβ-74cit69-81 peptide led to a population of HLA-DR4Fibβ-74cit69-81 tetramer+ T cells that exhibited biased T cell receptor (TCR) β chain usage, which was attributable to selective clonal expansion from the preimmune repertoire. Crystal structures of pre- and postimmune TCRs showed that the SE of HLA-DR4 represented a main TCR contact zone. Immunization with a double citrullinated epitope (Fibβ-72,74cit69-81) altered the responding HLA-DR4 tetramer+ T cell repertoire, which was due to the P2-citrulline residue interacting with the TCR itself. We show that the SE of HLA-DR4 has dual functionality, namely, presentation and a direct TCR recognition determinant. Analogous biased TCR β chain usage toward the Fibβ-74cit69-81 peptide was observed in healthy HLA-DR4+ individuals and patients with HLA-DR4+ RA, thereby suggesting a link to human RA.


2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Che-Mai Chang ◽  
Yu-Wen Hsu ◽  
Henry Sung-Ching Wong ◽  
James Cheng-Chung Wei ◽  
Xiao Liu ◽  
...  

Rheumatoid arthritis (RA) is a systematic autoimmune disease, predominantly causing chronic polyarticular inflammation and joint injury of patients. For the treatment of RA, biologic disease-modifying antirheumatic drugs (bDMARDs) have been used to reduce inflammation and to interfere with disease progression through targeting and mediating the immune system. Although the therapeutic effects of bDMARDs in RA patients have been widely reported, whether these drugs also play important roles in T-cell repertoire status is still unclear. We therefore designed the study to identify the role of T-cell repertoire profiles in RA patients with different types of bDMARD treatments. A high-throughput sequencing approach was applied to profile the T-cell receptor beta chain (TCRB) repertoire of circulating T lymphocytes in eight patients given adalimumab (anti-TNF-α) with/without the following use of either rituximab (anti-CD20) or tocilizumab (anti-IL6R). We subsequently analyzed discrepancies in the clonal diversity and CDR3 length distribution as well as usages of the V and J genes of TCRB repertoire and interrogated the association between repertoire diversity and disease activities followed by the treatment of bDMARDs in these RA patients. All groups of patients showed well-controlled DAS28 scores (<2.6) after different treatment regimens of drugs and displayed no significant statistical differences in repertoire diversity, distribution of CDR3 lengths, and usage of V and J genes of TCRB. Nonetheless, a trend between overall TCRB repertoire diversity and disease activity scores in all bDMARD-treated RA patients was observed. Additionally, age was found to be associated with repertoire diversity in RA patients treated with bDMARDs. Through the profiling of the TCR repertoire in RA patients receiving different biologic medications, our study indicated an inverse tendency between TCR repertoire diversity and disease activity after biologic treatment in RA patients.


EBioMedicine ◽  
2015 ◽  
Vol 2 (12) ◽  
pp. 2037-2045 ◽  
Author(s):  
Gabriele Di Sante ◽  
Barbara Tolusso ◽  
Anna Laura Fedele ◽  
Elisa Gremese ◽  
Stefano Alivernini ◽  
...  

2015 ◽  
Vol 13 (1) ◽  
pp. 12 ◽  
Author(s):  
Luisa Imberti ◽  
Mirko Scarsi ◽  
Cinzia Zanotti ◽  
Marco Chiarini ◽  
Diego Bertoli ◽  
...  

Author(s):  
Che-Mai Chang ◽  
Yu-Wen Hsu ◽  
Henry Sung-Ching Wong ◽  
Hsien-Tzung Liao ◽  
Wei-Chiao Chang

Sign in / Sign up

Export Citation Format

Share Document